Literature DB >> 2789261

Murine cell lines stably expressing the influenza virus hemagglutinin gene introduced by a recombinant retrovirus vector are constitutive targets for MHC class I- and class II-restricted T lymphocytes.

K B Eager1, C J Hackett, W U Gerhard, J Bennink, L C Eisenlohr, J Yewdell, R P Ricciardi.   

Abstract

A retrovirus vector containing the hemagglutinin (HA) gene of influenza virus was constructed and used to infect murine cell lines of fibroblast, mastocytoma and B cell lineages which are able to present antigens to MHC-restricted T cells. Stable cell lines were selected in which the retrovirus vector integrated as a single copy in almost all of the individual cell clones examined. The HA mRNA was shown to be of the expected length by Northern blot analysis, but the levels varied among the cell clones. Although the HA transcript was difficult to detect in any of the retrovirus-infected cell clones derived from fibroblasts, HA Ag was easily detected on the cell surface by cytofluorographic analysis. Significantly, retrovirus-infected clones derived from each cell type were recognized by HA-specific class I and class II MHC-restricted T lymphocytes. HA produced in these cells was able to be acquired, processed, and presented to class II-restricted T cells by additional, non-HA-expressing APC. This indicates that HA endogenously synthesized within these cell lines is available for Ag processing by an exogenous route.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2789261

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Influenza in senescent mice: impaired cytotoxic T-lymphocyte activity is correlated with prolonged infection.

Authors:  B S Bender; M P Johnson; P A Small
Journal:  Immunology       Date:  1991-04       Impact factor: 7.397

2.  Mast cells enhance T cell activation: Importance of mast cell-derived TNF.

Authors:  Susumu Nakae; Hajime Suto; Maki Kakurai; Jonathon D Sedgwick; Mindy Tsai; Stephen J Galli
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-19       Impact factor: 11.205

3.  Class II-restricted presentation of an endogenously derived immunodominant T-cell determinant of hen egg lysozyme.

Authors:  A Brooks; S Hartley; L Kjer-Nielsen; J Perera; C C Goodnow; A Basten; J McCluskey
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

4.  Demonstration of MHC class II-restricted cytotoxic T lymphocytes in mice against herpes simplex virus.

Authors:  G Kolaitis; M Doymaz; B T Rouse
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

5.  Human immunodeficiency virus vectors for inducible expression of foreign genes.

Authors:  G L Buchschacher; A T Panganiban
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

6.  Targeting a polyepitope protein incorporating multiple class II-restricted viral epitopes to the secretory/endocytic pathway facilitates immune recognition by CD4+ cytotoxic T lymphocytes: a novel approach to vaccine design.

Authors:  S A Thomson; S R Burrows; I S Misko; D J Moss; B E Coupar; R Khanna
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

7.  Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display.

Authors:  Carol S Leung; Tracey A Haigh; Laura K Mackay; Alan B Rickinson; Graham S Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-19       Impact factor: 11.205

8.  Anchor sequence-dependent endogenous processing of human immunodeficiency virus 1 envelope glycoprotein gp160 for CD4+ T cell recognition.

Authors:  M Polydefkis; S Koenig; C Flexner; E Obah; K Gebo; S Chakrabarti; P L Earl; B Moss; R F Siliciano
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

9.  Processing of a viral glycoprotein in the endoplasmic reticulum for class II presentation.

Authors:  S M Bartido; S Diment; C S Reiss
Journal:  Eur J Immunol       Date:  1995-08       Impact factor: 5.532

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.